Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OmniAb, Inc.OABI · Entity 5294 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OmniAb, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 185,274 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Exercise / conversion · Acquired 20,000 · Balance 185,274 F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Exercise / conversion · Disposed 20,000 · Balance 0 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2026-06-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-17 · Grant · Acquired 20,000 · Balance 20,000 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03 · Expires 2036-06-17 | Direct | 40,000 |
Reported balance
After 2026-06-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-17 · Grant · Acquired 40,000 · Balance 40,000 F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LIGAND PHARMACEUTICALS INC
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,161 |
Reported balance
After 2022-11-01 transaction · row 1
1 source rowRow 1 · 2022-11-01 · Disposition to issuer · Disposed 1,004 · Balance 1,161 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.68 · Expires 2032-06-10 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 4,340 · Balance 0 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2: The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
F2: The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 20:32 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001872349-26-000002 · wk-form4_1781814738.xml · derivative · entry 4 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-17 F4 · derivative.exercise_date: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:32 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001872349-26-000002 · wk-form4_1781814738.xml · derivative · entry 3 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F3 · derivative.expiration_date: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:32 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001872349-26-000002 · wk-form4_1781814738.xml · derivative · entry 2 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F1 · derivative.expiration_date: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:32 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001872349-26-000002 · wk-form4_1781814738.xml · nonDerivative · entry 1 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:12 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001872349-25-000004 · wk-form4_1750277528.xml · derivative · entry 4 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-17 F4 · derivative.exercise_date: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:12 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001872349-25-000004 · wk-form4_1750277528.xml · derivative · entry 3 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F3 · derivative.expiration_date: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:12 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001872349-25-000004 · wk-form4_1750277528.xml · derivative · entry 2 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU granted on June 18, 2024, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F1 · derivative.expiration_date: Represents the vesting of an RSU granted on June 18, 2024, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:12 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001872349-25-000004 · wk-form4_1750277528.xml · nonDerivative · entry 1 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU granted on June 18, 2024, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 15, 2025 Filed May 15, 2025 20:02 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 30,000 | $1.52 | $45,600.00 |
DisclosureSEC source: 0001628280-25-025856 · wk-form4_1747339327.xml · nonDerivative · entry 1 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,274 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.51 to $1.52. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2024 Filed Jul 12, 2024 20:59 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionRestricted Stock Units · Derivative | 1,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001846253-24-000065 · wk-form4_1720817981.xml · derivative · entry 2 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 1,896 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU which occurs in two equal annual installments, beginning July 12th, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. F1 · derivative.expiration_date: Represents the vesting of an RSU which occurs in two equal annual installments, beginning July 12th, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| July 12, 2024 Filed Jul 12, 2024 20:59 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 1,896 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001846253-24-000065 · wk-form4_1720817981.xml · nonDerivative · entry 1 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU which occurs in two equal annual installments, beginning July 12th, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 21:02 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0001846253-24-000052 · wk-form4_1719003731.xml · derivative · entry 4 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-06-18 F4 · derivative.exercise_date: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 21:02 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001846253-24-000052 · wk-form4_1719003731.xml · derivative · entry 3 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,896 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F3 · derivative.expiration_date: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 21:02 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001846253-24-000052 · wk-form4_1719003731.xml · derivative · entry 2 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,896 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F1 · derivative.expiration_date: Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 21:02 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001846253-24-000052 · wk-form4_1719003731.xml · nonDerivative · entry 1 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| July 12, 2023 Filed Jul 14, 2023 20:19 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionRestricted Stock Units · Derivative | 1,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001846253-23-000088 · edgardoc.xml · derivative · entry 2 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,896 Underlying: Common Stock · 1,896 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Vesting occurs in two equal annual installments, beginning July 12th, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. F1 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Vesting occurs in two equal annual installments, beginning July 12th, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. F1 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Vesting occurs in two equal annual installments, beginning July 12th, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| July 12, 2023 Filed Jul 14, 2023 20:19 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 1,896 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001846253-23-000088 · edgardoc.xml · nonDerivative · entry 1 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Vesting occurs in two equal annual installments, beginning July 12th, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 21:56 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001846253-23-000085 · primary_doc.xml · derivative · entry 4 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-23 F4 · derivative.exercise_date: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the annual meeting of the Company's stockholders next following the grant date and (B) on the first anniversary of the date of grant. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 21:56 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001846253-23-000085 · primary_doc.xml · derivative · entry 3 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,792 Underlying: Common Stock · 20,000 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. F3 · derivative.exercise_date: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. F3 · derivative.expiration_date: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 19:28 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 75,680 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001846253-23-000010 · edgardoc.xml · derivative · entry 2 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,680 Underlying: Common Stock · 75,680 shares Expires 2033-01-30 F2 · derivative.exercise_date: The stock option fully vests on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) on the first Grant Date Anniversary. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 19:28 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantCommon Stock | 17,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001846253-23-000010 · edgardoc.xml · nonDerivative · entry 1 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,982 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSU fully vests on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) on the first Grant Date Anniversary. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 22:57 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 22,250 | $3.75 | $83,526.50 |
DisclosureSEC source: 0000899243-22-038003 · doc4.xml · nonDerivative · entry 1 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,476 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.55 to $3.835. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 21:30 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 30,000 | $3.10 | $92,928.00 |
DisclosureSEC source: 0000899243-22-035694 · doc4.xml · nonDerivative · entry 1 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,226 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.99 to $3.15. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 4,340 | Not disclosed Strike: $90.68 | Not disclosed |
DisclosureSEC source: 0000899243-22-035044 · doc4.xml · derivative · entry 2 Cochran Jennifer R. · CIK 0001872349 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,340 shares Expires 2032-06-10 F1 · kind: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F1 · price: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2 · derivative.exercise_date: The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Disposition to issuerCommon Stock | 1,004 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035044 · doc4.xml · nonDerivative · entry 1 Cochran Jennifer R. · CIK 0001872349 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,161 F1 · kind: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F1 · price: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:19 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 37,840 | Not disclosed Strike: $9.10 | Not disclosed |
DisclosureSEC source: 0000899243-22-035066 · doc4.xml · derivative · entry 3 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,840 Underlying: Common Stock · 37,840 shares Expires 2032-06-10 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F5 · derivative.exercise_date: The stock option fully vests on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) on June 10, 2023. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:19 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 19,298 | Not disclosed Strike: $14.50 | Not disclosed |
DisclosureSEC source: 0000899243-22-035066 · doc4.xml · derivative · entry 2 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,298 Underlying: Common Stock · 19,298 shares Expires 2031-07-12 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option vests and is exercisable in three substantially equal annual installments beginning on July 12, 2022. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:19 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantCommon Stock | 25,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035066 · doc4.xml · nonDerivative · entry 1 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,226 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F2 · shares: Includes 12,545 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F3 · shares: Includes 10,784 earn-out shares subject to forfeiture provisions described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. Read SEC document |
| November 01, 2022 Filed Apr 23, 2024 21:40 UTC Amendment | OmniAb, Inc. OABI · Entity 5294 | GrantCommon Stock | 25,518 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001846253-24-000011 · wk-form4a_1713908398.xml · nonDerivative · entry 1 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,378 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F2 · shares: This amendment is being filed to correct a Form 4 filed on November 3, 2022, which inadvertently understated the number of shares beneficially held by the Reporting Person following the transaction reported by 292 shares. The number reported in column 4 represents the correct number of shares acquired by the Reporting Person as of November 1, 2022, which included (1) 12,545 restricted stock units and (2) 11,076 earn-out shares. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F3 · balance_after: Represents the number of shares beneficially held by the Reporting Person as of the date of this filing, as adjusted for the administrative error identified in footnote 2. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 22:47 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,340 | $0.00 Strike: $79.29 | $0.00 |
DisclosureSEC source: 0000886163-22-000083 · edgardoc.xml · derivative · entry 2 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,340 Underlying: Common Stock · 4,340 shares Expires 2032-06-10 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 22:47 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,004 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000083 · edgardoc.xml · nonDerivative · entry 1 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,165 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| July 12, 2021 Filed Jul 15, 2021 00:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,508 | $0.00 Strike: $126.36 | $0.00 |
DisclosureSEC source: 0000886163-21-000108 · edgardoc.xml · derivative · entry 2 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,508 Underlying: Common Stock · 4,508 shares Expires 2031-07-12 F1 · derivative.exercise_date: The option becomes exercisable in 3 successive annual installments upon completion of each calendar year of service beginning on the grant date. Read SEC document |
| July 12, 2021 Filed Jul 15, 2021 00:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,161 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-21-000108 · edgardoc.xml · nonDerivative · entry 1 Cochran Jennifer R. · CIK 0001872349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,161 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.